当前位置:首页 - 行情中心 - 冠昊生物(300238) - 财务分析 - 利润表

冠昊生物

(300238)

  

流通市值:28.48亿  总市值:28.48亿
流通股本:2.65亿   总股本:2.65亿

利润表

报告期2023-12-312023-09-302023-06-302023-03-31
公司类型通用通用通用通用
一、营业总收入404,178,697.25308,949,013.47210,814,871.09112,684,910.79
营业收入404,178,697.25308,949,013.47210,814,871.09112,684,910.79
二、营业总成本360,489,232.61258,011,428.97178,230,785.3787,034,936.18
营业成本84,366,507.0960,492,760.4147,231,514.1125,605,230.31
税金及附加4,367,281.133,126,318.092,149,923.091,000,958.77
销售费用166,536,462.51124,263,910.2582,819,956.6236,778,009.09
管理费用55,366,142.2737,204,507.3623,711,909.9513,595,191.91
研发费用44,503,865.8230,545,444.7620,208,810.369,567,734.69
财务费用5,348,973.792,378,488.12,108,671.24487,811.41
其中:利息费用1,782,364.351,391,084.081,019,107.91526,665.06
其中:利息收入1,502,794.741,148,471.09761,848.52368,610.32
加:投资收益-3,640,197.33-3,545,128.16-2,106,072.44-93,124.14
资产处置收益924,105.58-5,019.56-5,019.56-5,019.56
资产减值损失(新)-3,890,692.8-3,273,656.612,359,867.66-107,792.58
信用减值损失(新)-9,278,234.44-4,675,356.53-2,972,586.96-670,636.77
其他收益6,184,116.154,915,968.743,989,762.012,981,540.83
营业利润平衡项目0000
四、营业利润33,988,561.844,354,392.3833,850,036.4327,754,942.39
加:营业外收入11,171.24100,962.2396,516.99109,347.65
减:营业外支出1,910,538.58472,338.1252,938.1939,688.06
利润总额平衡项目0000
五、利润总额32,089,194.4643,983,016.4933,893,615.2327,824,601.98
减:所得税费用11,016,656.945,850,031.943,687,741.473,750,812.81
六、净利润21,072,537.5238,132,984.5530,205,873.7624,073,789.17
持续经营净利润21,072,537.5238,132,984.5530,205,873.7624,073,789.17
归属于母公司股东的净利润31,005,798.5841,271,327.2730,743,377.1722,115,265.7
少数股东损益-9,933,261.06-3,138,342.72-537,503.411,958,523.47
(一)基本每股收益0.120.160.120.08
(二)稀释每股收益0.120.160.120.08
八、其他综合收益4,244,210.952,670,524.541,215,900.121,730,956.42
归属于母公司股东的其他综合收益4,244,210.952,670,524.541,215,900.121,730,956.42
九、综合收益总额25,316,748.4740,803,509.0931,421,773.8825,804,745.59
归属于母公司股东的综合收益总额35,250,009.5343,941,851.8131,959,277.2923,846,222.12
归属于少数股东的综合收益总额-9,933,261.06-3,138,342.72-537,503.411,958,523.47
公告日期2024-03-062023-10-252023-08-232023-04-20
审计意见(境内)标准无保留意见
TOP↑